Endocrinology, Diabetes & Metabolism (Jan 2022)

One‐year trends from the LANDMARC trial: A 3‐year, pan‐India, prospective, longitudinal study on the management and real‐world outcomes of type 2 diabetes mellitus

  • Ashok K. Das,
  • Sanjay Kalra,
  • Shashank Joshi,
  • Ambrish Mithal,
  • Prasanna Kumar K. M.,
  • Ambika G. Unnikrishnan,
  • Hemant Thacker,
  • Bipin Sethi,
  • Subhankar Chowdhury,
  • Romik Ghosh,
  • Sukanya Krishnan,
  • Arjun Nair,
  • Senthilnathan Mohanasundaram,
  • Shalini K. Menon,
  • Vaibhav Salvi,
  • Deepa Chodankar,
  • Saket Thaker,
  • Chirag Trivedi,
  • Subhash K. Wangnoo,
  • Abdul H. Zargar,
  • Nadeem Rais

DOI
https://doi.org/10.1002/edm2.316
Journal volume & issue
Vol. 5, no. 1
pp. n/a – n/a

Abstract

Read online

Abstract Introduction Longitudinal data on management and progression of type 2 diabetes mellitus (T2DM) in India are scarce. LANDMARC (CTRI/2017/05/008452), first‐of‐its‐kind, pan‐India, prospective, observational study aimed to evaluate real‐world patterns and management of T2DM over 3 years. Methods Adults (≥25 to ≤60 years old at T2DM diagnosis; diabetes duration ≥2 years at enrolment; controlled/uncontrolled on ≥2 anti‐diabetic agents) were enrolled. The first‐year trends for glycaemic control, therapy and diabetic complications, including those from metropolitan and non‐metropolitan cities are reported here. Results Of 6236 enrolled participants, 5654 completed 1 year in the study. Although the overall mean glycated haemoglobin (HbA1c) improved by 0.5% (baseline: 8.1%) at 1 year, only 20% of the participants achieved HbA1c 3 vs. ≤3 OADs. Conclusions First‐year trends of the LANDMARC study offer insights into real‐world disease progression, suggesting the need for controlling risk factors and timely treatment intensification in people with T2DM.

Keywords